Trial · NCT06498687
Theophylline Nasal Spray for PD-Related Hyposmia and Anosmia
NCT06498687, Phase 1, Withdrawn, University of Nebraska
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Theophylline Nasal Spray for PD-Related Hyposmia and Anosmia. Trials, record NCT06498687. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06498687
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Theophylline Nasal Spray for PD-Related Hyposmia and Anosmia
- NCT number
- NCT06498687
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- University of Nebraska
- Conditions
- Hyposmia, Anosmia
- Interventions
- CYR-064
- First posted
- 2024-07-12
- Last updated
- 2025-03-13
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Numeric Rating Scale-11 Smell-Patient Reported Outcome (PRO) (NRS-11-PRO): Improvement | baseline to week 24 | Improvement in patient-reported paper diary (scale 0-10). Score of 0="I cannot smell anything", to 10="My sense of smell is normal to me" |
| Primary | Numeric Rating Scale-11 Taste-Patient Reported Outcome (PRO) (NRS-11-PRO): Improvement | baseline to week 24 | Improvement in patient-reported paper diary (scale 0-10). Score of 0="I could not taste food", to 10="My food tastes normal to me" |
| Primary | Numeric Rating Scale-11 Smell-Patient Reported Outcome (PRO) (NRS-11-PRO): Mean Change | baseline to week 24 | Mean Change in patient-reported paper diary (scale 0-10) of sense of smell. Score of 0="I cannot smell anything", to 10="My sense of smell is normal to me" |
| Primary | Numeric Rating Scale-11 Taste-Patient Reported Outcome (PRO) (NRS-11-PRO): Mean Change | baseline to week 24 | Mean Change in patient-reported paper diary (scale 0-10) of ability to taste food. Score of 0="I could not taste food", to 10="My food tastes normal to me" |
| Secondary | Cumulative Adverse Events (AEs) | baseline to week 24 | Cumulative adverse events related to CYR-064 |
| Secondary | Cumulative Serious Adverse Events (SAEs) | baseline to week 24 | Cumulative serious adverse events related to CYR-064 |
| Secondary | Cumulative Suspected, Unexpected, Serious Adverse Events Related (SUSARs) | baseline to week 24 | Cumulative Suspected, Unexpected, Serious Adverse Events Related to CYR-064 |
| Other | Change in Sniffin' Sticks Threshold, Detection and Identification (TDI) Scores | baseline to week 24 | Individual and cumulative scores of odor threshold, detection and identification. Individual scores of odor threshold, detection and identification which are combined for a global score of olfaction. Scores \<16 indicate anosmia, 16-31 indicate hyposmia and \>31 indicate normosmia. |
| Other | Mean Change in Sniffin' Sticks Threshold, Detection and Identification (TDI) Scores | baseline to week 24 | Individual scores of odor threshold, detection and identification which are combined for a global score of olfaction. Scores \<16 indicate anosmia, 16-31 indicate hyposmia and \>31 indicate normosmia. |
| Other | Numeric Rating Scale-11 Smell-Patient Reported Outcome (PRO) (NRS-11 Smell Impact-PRO Score) | baseline to week 24 | Scale of 0-10 of hyposmia: Score of 0="I cannot smell anything", to 10="My sense of smell is normal to me" |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers38
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06498687
GET https://conductscience.org/api/trials/v1/NCT06498687/papers?page=2